Testing effectiveness (Phase 2)Ended earlyNCT05068284
What this trial is testing
Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
Who this might be right for
Crohn's Disease
AbbVie 176